Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1

Status

Terminated 2Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Plasma cell 2Other hematologic neoplasm 1

Conditions

Neoplasms 5Multiple Myeloma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Recurrence 1Platinum-resistant Ovarian Cancer 1Metastatic Castration-resistant Prostate Cancer 1Hematologic Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neoplasms × afuresertib × Clear all
NCT02177682 2021-08-11

Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients

Novartis

Phase 1 Terminated
9 enrolled
Plasma cell

Multiple Myeloma, Neoplasms

NCT01531894 2019-07-09

Continuation Study of the Oral AKT Inhibitor GSK2110183

Novartis

Phase 2 Completed
11 enrolled 8 charts
Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT02240212 2017-04-11

Study of Afuresertib Combined With Paclitaxel in Gastric Cancer

Novartis

Phase 1 Completed
29 enrolled
Tumor-Agnostic

Neoplasms

NCT02380313 2016-10-06

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

GlaxoSmithKline

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT02235740 2016-05-04

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

Novartis

Phase 1 Terminated
1 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡